Trial Profile
A Phase 1/1B Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study Of DS-6051b, An Oral ROS1 And NTRK Inhibitor, In Subjects With Metastatic and/or Unresectable Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Apr 2023
Price :
$35
*
At a glance
- Drugs Taletrectinib (Primary)
- Indications Neuroendocrine tumours; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors AnHeart Therapeutics; Daiichi Sankyo Inc
- 31 Mar 2023 According to an AnHeart Therapeutics media release, the company presented updated results from a pooled analysis including patients from this, NCT04395677, and NCT02675491 trials, in an oral presentation at the European Lung Cancer Congress (ELCC) 2023.
- 29 Oct 2020 Pooled analysis of two Phase 1 trials (NCT02279433 and NCT02675491) published in the AnHeart Therapeutics Media Release.
- 29 Oct 2020 According to an AnHeart Therapeutics, the company announced publication of a pooled analysis of two Phase 1 trials (NCT02279433 and NCT02675491) in JTO Clinical and Research Reports, an official journal of the International Association for the Study of Lung Cancer. Dr. Sai-Hong Ignatius Ou, MD PhD was the lead and corresponding author of this publication.